Literature DB >> 9766486

Arthritis in HLA-B27 transgenic animals.

J D Taurog1.   

Abstract

This review focuses on investigations of rats and mice transgenic for HLA-B27; these animals have been investigated for several years as potential models for the human spondyloarthropathies. Spontaneous multisystem disease occurs in rats with high expression of B27 and human beta2-microglobulin (hbeta2m). The disease is T-cell-dependent and is sensitive to both environmental and genetic manipulation. A spontaneous arthritis and enthesopathy has been observed by some investigators in nontransgenic mice which seems to be more prevalent in B27 transgenic mice. Peripheral arthritis has also been reported in B27 transgenic mice that lack mouse beta2m. Potential insights from these animals into the pathogenesis of B27-related disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766486     DOI: 10.1097/00000441-199810000-00005

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

Review 1.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Animal models of ankylosing spondylitis.

Authors:  Yiping Zhang; Shuilang Shi; Christina Ciurli; A Robin Poole
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

Review 3.  A molecular insight on the association of HLA-B27 with spondyloarthropathies.

Authors:  M Martí; I Alvarez; J A López de Castro
Journal:  Curr Rheumatol Rep       Date:  1999-10       Impact factor: 4.592

4.  The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis.

Authors:  James C Keith; Leo M Albert; Yelena Leathurby; Max Follettie; Lili Wang; Lisa Borges-Marcucci; Christopher C Chadwick; Robert J Steffan; Douglas C Harnish
Journal:  Arthritis Res Ther       Date:  2005-02-21       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.